NCT07712939
A Phase 1, First-in-Human Study of CND319 in Healthy Participants and Patients With Rheumatic Diseases
Recruiting · Phase 1 · Candid Therapeutics · registry updated 2026-07-22
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary clinical activity of CND319 in healthy adult participants and patients with rheumatic diseases.
Inclusion
- Inclusion Criteria (SAD):
- to 65 years old
- Body mass index 18-30 kg/m2 and weight 55-100 kg
- Individuals in good health
- Agree to abstain from consumption of alcohol 48 hours prior to study visits
- Agree to the use of highly effective contraception as defined in the protocol
Exclusion
- Exclusion Criteria (SAD):
- Inadequate clinical laboratory parameters at Screening
- Active infection
- Receipt of or inability to discontinue any excluded therapies
- Individuals with immediate household contact with your children (eg, ≤ 6 years old) or immunocompromised persons
- History of alcohol or drug abuse within last 12 months